XTX Topco Ltd Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

XTX Topco Ltd purchased a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 13,657 shares of the biotechnology company’s stock, valued at approximately $688,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CORT. Mariner LLC boosted its holdings in shares of Corcept Therapeutics by 13.6% during the 4th quarter. Mariner LLC now owns 13,362 shares of the biotechnology company’s stock valued at $673,000 after buying an additional 1,601 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in Corcept Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,459 shares of the biotechnology company’s stock valued at $426,000 after acquiring an additional 268 shares during the period. Bank of Montreal Can boosted its stake in Corcept Therapeutics by 8.9% during the fourth quarter. Bank of Montreal Can now owns 13,678 shares of the biotechnology company’s stock worth $689,000 after acquiring an additional 1,122 shares in the last quarter. Federated Hermes Inc. grew its holdings in Corcept Therapeutics by 107.1% in the fourth quarter. Federated Hermes Inc. now owns 13,870 shares of the biotechnology company’s stock worth $699,000 after purchasing an additional 7,172 shares during the period. Finally, Quadrant Capital Group LLC grew its holdings in Corcept Therapeutics by 9.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,969 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 257 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction on Monday, February 10th. The stock was sold at an average price of $68.08, for a total value of $149,776.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 35,102 shares of the company’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $94.72, for a total value of $3,324,861.44. Following the sale, the chief executive officer now owns 2,982,335 shares of the company’s stock, valued at approximately $282,486,771.20. This trade represents a 1.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 163,124 shares of company stock worth $15,117,614 over the last three months. 20.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. StockNews.com cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. HC Wainwright boosted their target price on Corcept Therapeutics from $115.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Canaccord Genuity Group raised their price target on Corcept Therapeutics from $130.00 to $142.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Truist Financial upped their price target on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, March 31st. Finally, Piper Sandler raised their price objective on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an “overweight” rating in a research note on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $143.25.

Corcept Therapeutics Stock Down 3.7 %

Corcept Therapeutics stock opened at $62.24 on Friday. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $117.33. The stock has a fifty day simple moving average of $65.66 and a two-hundred day simple moving average of $58.08. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The firm has a market cap of $6.57 billion, a price-to-earnings ratio of 49.40 and a beta of 0.15.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.11). The business had revenue of $181.89 million during the quarter, compared to the consensus estimate of $200.12 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. Equities analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.